Figure 2

Suppression of BST-2 in cancer cells increases tumor latency and decreases tumor mass in vivo. (A) Knockdown of endogenous BST-2 expression in 4T1 cells increases tumor latency computed as (number of tumor-free injected mice/number of injected mice) x100. (B) Tumor volume (TV) computed as TV = 0.5 (length*width²) over time is significantly reduced when BST-2 is suppressed in 4T1 cells. (C) Tumor cells tracked in vivo with IVIS imaging system show significant reduction in luciferase expression in BST-2-suppressed sh413 compared to BST-2-expressing shControl injected mice. (D) Loss of BST-2 in cancer cells reduced tumor mass. Tumor weight (numbers, g) and gross images obtained at necropsy are shown. All mice implanted with 4T1 shControl or sh413 cells developed mammary tumors with variation in size. Numbers represent average ± SEM. Scale bar = 5 mm.